MA5-12135 targets Cytokeratin HMW and it recognizes keratin 1, 5, 10, and 14 in the Moll catalog (MW 68kDa, 58kDa, 56.5kDa, and 50kDa), respectively. The antibody has been tested in ICC/IF, WB and IHC (P) applications and shows reactivity with Equine, Human, Non-human primate, and Rabbit samples. This antibody does not react with rat tissue in Western blot applications.
In normal cells, Cytokeratin HMW labels squamous, ductal and other complex epithelia. It reacts with benign small-acinir lesions of the prostate and does not react with hepatocytes, pancreatic acinar cells, proximal renal tubes or endometrial glands. In tumor cells, this antibody is reactive with both squamous and ductal neoplasms and variably with those derived from simple epithelium.
The MA5-12135 immunogen is solubilized keratin extracted from human stratum corneum.
Keratins are heteropolymeric structural proteins that form the intermediate filament. Cytokeratins are intermediate filament keratins found in the intracytoplasmic cytoskeleton of epithelial tissue. There are two types of cytokeratins – the low weight, acidic type I and the high weight, basic type II. Cytokeratins are usually found in pairs – one type I and one type II.
KRT1 regulates the activity of kinases such as PKC and SRC via binding to integrin beta-1 (ITB1) and the receptor of activated protein C kinase I (RACK1). In complex with C1QBP it is a high affinity receptor for kininogen-1/HMWK. KRT1 is expressed in the spinous and granular layers of the epidermis with family member KRT10. Mutations affecting the gene result in bullous congenital ichthyosiform erythroderma.
KRT5 is specifically expressed in the basal layer of the epidermis with family member KRT14. Mutations affecting the gene result in epidermolysis bullosa simplex diseases.
KRT10 plays a role in the establishment of the epidermal barrier on plantar skin. It also acts as a mediator of S.aureus adherence to desquamated nasal epithelial cells via clfB – thus it plays a role in nasal colonization. Mutations affecting the gene result in epidermolytic hyperkeratosis.
KRT14's nonhelical tail domain is involved in promoting KRT5-KRT14 filaments to self-organize into large bundles and enhances the mechanical properties involved in resilience of keratin intermediate filaments in vitro. Mutations affecting the gene result in epidermolysis bullosa simplex.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Protein Aliases: 58 kDa cytokeratin; 67 kDa cytokeratin; CK-1; CK-10; CK-14; CK-5; cytokeratin 1; cytokeratin 10; cytokeratin 14; Cytokeratin-1; Cytokeratin-10; Cytokeratin-14; Cytokeratin-5; epidermolysis bullosa simplex 2 Dowling-Meara/Kobner/Weber-Cockayne types; epidermolytic hyperkeratosis 1; Hair alpha protein; K1; K10; K14; K5; keratin 1, type II; keratin 10; keratin 10, type I; keratin 14, type I; keratin 5 (epidermolysis bullosa simplex, Dowling-Meara/Kobner/Weber-Cockayne types); keratin 5, type II; keratin 5-like; keratin 6A-like; Keratin, type I cytoskeletal 10; Keratin, type I cytoskeletal 14; Keratin, type II cytoskeletal 1; Keratin, type II cytoskeletal 5; Keratin-1; Keratin-10; Keratin-14; Keratin-5; Type-II keratin Kb1; Type-II keratin Kb5
Gene Aliases: BCIE; BIE; CK1; CK10; CK14; CK5; DDD; DDD1; EBS2; EBS3; EBS4; EHK; EHK1; EPPK; K1; K10; K14; K5; KPP; KRT1; KRT10; KRT14; KRT1A; KRT5; KRT5A; KRTA; NEPPK; NFJ